Global Indemnity Group, LLCGBLI

Global Indemnity Group, LLC reported Q1 2026 revenues of $109.2 million, net income of $4.2 million, and diluted EPS of $0.29 on 14.4 million diluted shares, according to its SEC 10-Q filed 2026-05-15. Cash and cash equivalents stood at $34.8 million while operating cash flow was -$17.9 million, painting a picture of a business that talks innovation but files classic P&C cash-flow math. Assets totalled $1.68 billion against liabilities of $976 million, leaving shareholders’ equity of $704.1 million-respectable for a specialty insurer, but the cash buffer is the tighter constraint.

Global Indemnity sells specialty insurance and reinsurance, with public pages showcasing products for cannabis, commercial auto, and equine markets that others overlook. The company style is consultative and policy-specific, which is catnip for brokers in niche segments, and its claims portal invites customers to file digitally. Yet the website’s promise of ‘innovative insurance solutions tailored to diverse needs’ collides with the XBRL reality of cash used in operations. When the marketing slide shows smiling underwriters and skylines, the cash-flow line shows red ink, and the gap matters to anyone who has to make a claims payment.

For the quarter ending 31 March 2026, Global Indemnity’s 10-Q lists revenues of $109.2 million, net income of $4.2 million, diluted EPS of $0.29, diluted shares of 14.4 million, cash and cash equivalents of $34.8 million, and operating cash flow of -$17.9 million. Liabilities totalled $976 million against assets of $1.68 billion, with shareholders’ equity at $704.1 million. The filing also discloses cash used in operations and the diluted share base, giving a clear picture of cash generation versus accounting profit. There is no forward-looking guidance in the 10-Q, and there is no segment-level breakdown beyond the public page description of specialty lines.

The company’s investor-relations page offers an email-alert sign-up and links to the SEC filings index, but no analyst-day transcript or formal guidance update. The product rail shows GBLI positioning itself in underserved niches like cannabis and equine, which can be a durable wedge if underwriting discipline holds, but the cash-flow math remains the binding constraint. Without a visible path to positive operating cash flow, the ability to scale specialty lines without diluting equity further is the central question.

GBLI’s public equity is quoted on its home market venue with daily liquidity driven by the free float; the SEC filings do not provide intraday volume data, so retail traders rely on the regional exchange’s time-and-sales feed rather than any SEC disclosure. There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available.

The latest 10-Q does not include formal guidance, and there is no earnings-call transcript in the evidence set. The site’s imagery shows smiling staff and underwriters, but the XBRL tables list cash used in operations, so the polished story and the spreadsheet tell different stories. The absence of segment-level cash-flow disclosure and forward-looking metrics leaves investors to infer how much of the $109.2 million revenue is cash-generative versus accruals-heavy. Until the next quarterly filing or an investor update, the file’s tension sits between niche growth aspirations and the cash-flow reality of running a specialty insurer in 2026.